Lupus-anticoagulant testing at NOAC trough levels

Thrombosis and Haemostasis

Volumn 116, Issue 2, 2016, Pages 235-240

  Ratzinger, Franz ^a   Lang, Mona ^a   Belik, Sabine ^a   Jilma Stohlawetz, Petra ^a   Schmetterer, Klaus G ^a   Haslacher, Helmuth ^a   Perkmann, Thomas ^a   Quehenberger, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulant; Coagulation; Laboratory testing; Lupus anticoagulant; Non vitamin K antagonist oral anticoagulants

Indexed keywords

APIXABAN; DABIGATRAN; LUPUS ANTICOAGULANT; RIVAROXABAN; VENOM; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ANTICOAGULATION; ARTICLE; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; FALSE POSITIVE RESULT; HUMAN; LABORATORY TEST; LIMIT OF QUANTITATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SCREENING; BLOOD; BLOOD CLOTTING TEST; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; PROCEDURES; PROTHROMBIN TIME; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FALSE POSITIVE REACTIONS; HUMANS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; RIVAROXABAN;

EID: 84980378072     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-02-0081     Document Type: Article

References (39)

1. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
2. Keeling D, Mackie I, Moore GW, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58.
3. CLSI CaLSI. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
4. Lakos G. Interference in Antiphospholipid Antibody Assays. Semin Thromb Hemost 2012; 38: 353-359.
5. Pollack CVJ, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520.
6. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931-942.
7. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373: 2413-2424.
8. Jacquemin M, Toelen J, Schoeters J, et al. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. J Thromb Haemost 2015; 13: 2087-2092.
9. Van Blerk M, Bailleul E, Chatelain B, et al. Influence of dabigatran and riva-roxaban on routine coagulation assays A nationwide Belgian survey. Thromb Haemost 2015; 113: 154-164.
10. Kitchen S, Gray E, Mackie I, et al. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 166: 830-841.
11. Mani H. Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol 2014; 36: 261-268.
12. Cuker A, Siegal DM, Crowther MA, et al. Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. J Am Coll Car-diol 2014; 64: 1128-1139.
13. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015; 53: 185-197.
14. Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 2012; 50: 1601-1605.
15. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2015; Epub ahead of print.
16. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
17. Curvers J, van de Kerkhof D, Stroobants AK, et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol 2012; 138: 551-558.
18. Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and riva-roxaban. Br J Haematol 2013; 163: 160-167.
19. Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012; 50: 1799-1807.
20. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chro-mogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
21. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of riva-roxaban and review of the literature. Thromb Res 2012; 130: 956-966.
22. Douxfils J, Mani H, Minet V, et al. Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Res Int 2015; Epub ahead of print.
23. Genzen JR, Miller JL. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol 2005; 124: 586-593.
24. Martinuzzo ME, Barrera LH, D'Adamo MA, et al. Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014; 36: 144-150.
25. Hillarp A, Gustafsson KM, Faxalv L, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014; 12: 1545-1553.
26. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacody-namics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776-786.
27. Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the phar-macokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: 179-187.
28. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
29. Moore GW. Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants. Semin Thromb Hemost 2014; 40: 163-171.
30. Gemen EF, Kariman MA, van Dijk JH, et al. Impact of dabigatran on routine and specific coagulation assays in patients treated by dabigatran. Ned Tijdschr Klin Chem Labgeneesk 2014; 39: 156-157.
31. Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016; 48: 60-71.
32. Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-294.
33. van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Hae-most 2011; 9: 1657-1659.
34. Arachchillage DR, Mackie IJ, Efthymiou M, et al. Interactions between riva-roxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015; 13: 1264-1273.
35. Triplett DA, Stocker KF, Unger GA, et al. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-931.
36. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
37. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
38. Favaloro EJ, Lippi G. Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. Semin Thromb Hemost 2015; 41: 208-227.
39. Douxfils J, Chatelain B, Hjemdahl P, et al. Does the Russell Viper Venomtime test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res 2015; 135: 852-860.